<DOC>
	<DOCNO>NCT01838317</DOCNO>
	<brief_summary>This study do determine whether addition oral medication , pioglitazone standard chemotherapy , result improvement blood test measure body 's ability utilize sugar ( glucose insulin metabolism ) . In addition investigator want determine whether treatment pioglitazone result ( 1 ) improvement size tumor , ( 2 ) weight gain , ( 3 ) improve ability function day ( 4 ) quality life .</brief_summary>
	<brief_title>A Phase II Study Pioglitazone Patients With Cancer Pancreas</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<criteria>Signed informed consent Histologically proven adenocarcinoma pancreas Radiologically measurable disease ECOG functional status 02 Prior radiation therapy pancreatic cancer If chemotherapy plan , new chemotherapy regimen start 14 day prior enrollment Surgery radiation plan within 8 week start therapy Prior exposure Thiazolidinedione ( TZD ) therapy past 12 month Hypersensitivity TZD New York heart association class III/IV heart failure . Known HIV positive Pregnant lactate woman History , active bladder cancer Inadequate hepatic function document within 14 day enrollment Total bilirubin level &gt; 1.5 x ULN AST ALT &gt; 2.5 x ULN , unless liver metastasis case AST ALT &gt; 5 x ULN</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>